MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells

Jagadeesh Setti Guthi, Su Geun Yang, Gang Huang, Shunzi Li, Chalermchai Khemtong, Chase W. Kessinger, Michael Peyton, John D. Minna, Kathlynn C. Brown, Jinming Gao

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Polymeric micelles are emerging as a highly integrated nanoplatform for cancer targeting, drug delivery and tumor imaging applications. In this study, we describe a multifunctional micelle (MFM) system that is encoded with a lung cancer-targeting peptide (LCP), and encapsulated with superparamagnetic iron oxide (SPIO) and doxorubicin (Doxo) for MR imaging and therapeutic delivery, respectively. The LCP-encoded MFM showed significantly increased αvβ6-dependent cell targeting in H2009 lung cancer cells over a scrambled peptide (SP)-encoded MFM control as well as in an αvβ6-negative H460 cell control. 3H-Labeled MFM nanoparticles were used to quantify the time- and dose-dependent cell uptake of MFM nanoparticles with different peptide encoding (LCP vs SP) and surface densities (20% and 40%) in H2009 cells. LCP functionalization of the micelle surface increased uptake of the MFM by more than 3-fold compared to the SP control. These results were confirmed by confocal laser scanning microscopy, which further demonstrated the successful Doxo release from MFM and accumulation in the nucleus. SPIO clustering inside the micelle core resulted in high T2 relaxivity (>400 Fe mM -1 s-1) of the resulting MFM nanoparticles. T 2-weighted MRI images showed clear contrast differences between H2009 cells incubated with LCP-encoded MFM over the SP-encoded MFM control. An ATP activity assay showed increased cytotoxicity of LCP-encoded MFM over SP-encoded MFM in H2009 cells (IC50 values were 28.3 ± 6.4 nM and 73.6 ± 6.3 nM, respectively; p < 0.005). The integrated diagnostic and therapeutic design of MFM nanomedicine potentially allows for image-guided, target-specific treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalMolecular Pharmaceutics
Volume7
Issue number1
DOIs
StatePublished - Feb 1 2010

Fingerprint

Nanomedicine
Micelles
Lung Neoplasms
Pharmaceutical Preparations
Peptides
Nanoparticles
Doxorubicin

Keywords

  • αβ integrin
  • Lung cancer therapy
  • Magnetic resonance imaging
  • Polymeric micelles
  • Superparamagnetic iron oxide
  • Theranostic nanomedicine; doxorubicin

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. / Guthi, Jagadeesh Setti; Yang, Su Geun; Huang, Gang; Li, Shunzi; Khemtong, Chalermchai; Kessinger, Chase W.; Peyton, Michael; Minna, John D.; Brown, Kathlynn C.; Gao, Jinming.

In: Molecular Pharmaceutics, Vol. 7, No. 1, 01.02.2010, p. 32-40.

Research output: Contribution to journalArticle

Guthi, Jagadeesh Setti ; Yang, Su Geun ; Huang, Gang ; Li, Shunzi ; Khemtong, Chalermchai ; Kessinger, Chase W. ; Peyton, Michael ; Minna, John D. ; Brown, Kathlynn C. ; Gao, Jinming. / MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. In: Molecular Pharmaceutics. 2010 ; Vol. 7, No. 1. pp. 32-40.
@article{60a24c08d9db4a4f95a73cfd7837c928,
title = "MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells",
abstract = "Polymeric micelles are emerging as a highly integrated nanoplatform for cancer targeting, drug delivery and tumor imaging applications. In this study, we describe a multifunctional micelle (MFM) system that is encoded with a lung cancer-targeting peptide (LCP), and encapsulated with superparamagnetic iron oxide (SPIO) and doxorubicin (Doxo) for MR imaging and therapeutic delivery, respectively. The LCP-encoded MFM showed significantly increased αvβ6-dependent cell targeting in H2009 lung cancer cells over a scrambled peptide (SP)-encoded MFM control as well as in an αvβ6-negative H460 cell control. 3H-Labeled MFM nanoparticles were used to quantify the time- and dose-dependent cell uptake of MFM nanoparticles with different peptide encoding (LCP vs SP) and surface densities (20{\%} and 40{\%}) in H2009 cells. LCP functionalization of the micelle surface increased uptake of the MFM by more than 3-fold compared to the SP control. These results were confirmed by confocal laser scanning microscopy, which further demonstrated the successful Doxo release from MFM and accumulation in the nucleus. SPIO clustering inside the micelle core resulted in high T2 relaxivity (>400 Fe mM -1 s-1) of the resulting MFM nanoparticles. T 2-weighted MRI images showed clear contrast differences between H2009 cells incubated with LCP-encoded MFM over the SP-encoded MFM control. An ATP activity assay showed increased cytotoxicity of LCP-encoded MFM over SP-encoded MFM in H2009 cells (IC50 values were 28.3 ± 6.4 nM and 73.6 ± 6.3 nM, respectively; p < 0.005). The integrated diagnostic and therapeutic design of MFM nanomedicine potentially allows for image-guided, target-specific treatment of lung cancer.",
keywords = "αβ integrin, Lung cancer therapy, Magnetic resonance imaging, Polymeric micelles, Superparamagnetic iron oxide, Theranostic nanomedicine; doxorubicin",
author = "Guthi, {Jagadeesh Setti} and Yang, {Su Geun} and Gang Huang and Shunzi Li and Chalermchai Khemtong and Kessinger, {Chase W.} and Michael Peyton and Minna, {John D.} and Brown, {Kathlynn C.} and Jinming Gao",
year = "2010",
month = "2",
day = "1",
doi = "10.1021/mp9001393",
language = "English (US)",
volume = "7",
pages = "32--40",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells

AU - Guthi, Jagadeesh Setti

AU - Yang, Su Geun

AU - Huang, Gang

AU - Li, Shunzi

AU - Khemtong, Chalermchai

AU - Kessinger, Chase W.

AU - Peyton, Michael

AU - Minna, John D.

AU - Brown, Kathlynn C.

AU - Gao, Jinming

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Polymeric micelles are emerging as a highly integrated nanoplatform for cancer targeting, drug delivery and tumor imaging applications. In this study, we describe a multifunctional micelle (MFM) system that is encoded with a lung cancer-targeting peptide (LCP), and encapsulated with superparamagnetic iron oxide (SPIO) and doxorubicin (Doxo) for MR imaging and therapeutic delivery, respectively. The LCP-encoded MFM showed significantly increased αvβ6-dependent cell targeting in H2009 lung cancer cells over a scrambled peptide (SP)-encoded MFM control as well as in an αvβ6-negative H460 cell control. 3H-Labeled MFM nanoparticles were used to quantify the time- and dose-dependent cell uptake of MFM nanoparticles with different peptide encoding (LCP vs SP) and surface densities (20% and 40%) in H2009 cells. LCP functionalization of the micelle surface increased uptake of the MFM by more than 3-fold compared to the SP control. These results were confirmed by confocal laser scanning microscopy, which further demonstrated the successful Doxo release from MFM and accumulation in the nucleus. SPIO clustering inside the micelle core resulted in high T2 relaxivity (>400 Fe mM -1 s-1) of the resulting MFM nanoparticles. T 2-weighted MRI images showed clear contrast differences between H2009 cells incubated with LCP-encoded MFM over the SP-encoded MFM control. An ATP activity assay showed increased cytotoxicity of LCP-encoded MFM over SP-encoded MFM in H2009 cells (IC50 values were 28.3 ± 6.4 nM and 73.6 ± 6.3 nM, respectively; p < 0.005). The integrated diagnostic and therapeutic design of MFM nanomedicine potentially allows for image-guided, target-specific treatment of lung cancer.

AB - Polymeric micelles are emerging as a highly integrated nanoplatform for cancer targeting, drug delivery and tumor imaging applications. In this study, we describe a multifunctional micelle (MFM) system that is encoded with a lung cancer-targeting peptide (LCP), and encapsulated with superparamagnetic iron oxide (SPIO) and doxorubicin (Doxo) for MR imaging and therapeutic delivery, respectively. The LCP-encoded MFM showed significantly increased αvβ6-dependent cell targeting in H2009 lung cancer cells over a scrambled peptide (SP)-encoded MFM control as well as in an αvβ6-negative H460 cell control. 3H-Labeled MFM nanoparticles were used to quantify the time- and dose-dependent cell uptake of MFM nanoparticles with different peptide encoding (LCP vs SP) and surface densities (20% and 40%) in H2009 cells. LCP functionalization of the micelle surface increased uptake of the MFM by more than 3-fold compared to the SP control. These results were confirmed by confocal laser scanning microscopy, which further demonstrated the successful Doxo release from MFM and accumulation in the nucleus. SPIO clustering inside the micelle core resulted in high T2 relaxivity (>400 Fe mM -1 s-1) of the resulting MFM nanoparticles. T 2-weighted MRI images showed clear contrast differences between H2009 cells incubated with LCP-encoded MFM over the SP-encoded MFM control. An ATP activity assay showed increased cytotoxicity of LCP-encoded MFM over SP-encoded MFM in H2009 cells (IC50 values were 28.3 ± 6.4 nM and 73.6 ± 6.3 nM, respectively; p < 0.005). The integrated diagnostic and therapeutic design of MFM nanomedicine potentially allows for image-guided, target-specific treatment of lung cancer.

KW - αβ integrin

KW - Lung cancer therapy

KW - Magnetic resonance imaging

KW - Polymeric micelles

KW - Superparamagnetic iron oxide

KW - Theranostic nanomedicine; doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=76249087483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249087483&partnerID=8YFLogxK

U2 - 10.1021/mp9001393

DO - 10.1021/mp9001393

M3 - Article

C2 - 19708690

AN - SCOPUS:76249087483

VL - 7

SP - 32

EP - 40

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 1

ER -